A regenerative approach for bone repair in congenital pseudarthrosis of the tibia associated or not associated with type 1 neurofibromatosis: Correlation between laboratory findings and clinical outcome

Cytotherapy

Volumn 14, Issue 3, 2012, Pages 306-314

  Granchi, Donatella ^a   Devescovi, Valentina ^a   Baglio, Serena Rubina ^a   Magnani, Marina ^a   Donzelli, Onofrio ^a   Baldini, Nicola ^a,b  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Bone regeneration; Congenital pseudarthrosis of the tibia; Mesenchymal stromal cells; Platelet concentrates; Type 1 neurofibromatosis

Indexed keywords

FIBRIN; PLATELET RICH FIBRIN; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; BONE REMODELING; CELL TRANSPLANTATION; CHILD; CLINICAL ARTICLE; CONGENITAL PSEUDARTHROSIS; CONGENITAL PSEUDARTHROSIS OF THE TIBIA; DISEASE ASSOCIATION; FEMALE; HUMAN; ILIAC CREST; INFANT; MALE; MESENCHYMAL STROMA CELL; NEUROFIBROMATOSIS; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME;

EID: 84856865964     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2011.627916     Document Type: Article

References (49)

1. Vander Have KL, Hensinger RN, Caird M, Johnston C, Farley FA. Congenital pseudarthrosis of the tibia. J Am Acad Orthop Surg. 2008;16:228-36.
2. Feldman DS, Jordan C, Fonseca L. Orthopaedic manifestations of neurofibromatosis type 1. J Am Acad Orthop Surg. 2010;18:346-57.
3. Hefti F, Bollini G, Dungl P, Fixsen J, Grill F, Ippolito E, et al. Congenital pseudarthrosis of the tibia: history, etiology, classification, and epidemiologic data. J Pediatr Orthop B. 2000;9:11-5. (Pubitemid 30044014)
4. Ohnishi I, Sato W, Matsuyama J, Yajima H, Haga N, Kamegaya M, et al. Treatment of congenital pseudarthrosis of the tibia: a multicenter study in Japan. J Pediatr Orthop. 2005;25:219-24. (Pubitemid 40315442)
5. Carney BT, Daniels CL. A retrospective review of congenital pseudarthrosis of the tibia. Iowa Orthop J. 2002;22:57-60.
6. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-7.
7. Brooke G, Cook M, Blair C, Han R, Heazlewood C, Jones B, et al. Therapeutic applications of mesenchymal stromal cells. Semin Cell Dev Biol. 2007;18:846-58. (Pubitemid 350138458)
8. Novicoff WM, Manaswi A, Hogan MV, Brubaker SM, Mihalko WM, Saleh KJ. Critical analysis of the evidence for current technologies in bone-healing and repair. J Bone Joint Surg Am. 2008;90(S1):85-91. (Pubitemid 351329126)
9. Hernigou P, Mathieu G, Poignard A, Manicom O, Beaujean F, Rouard H. Percutaneous autologous bone-marrow grafting for nonunions. Surgical technique. J Bone Joint Surg Am. 2006;88(S1):322-7.
10. Garg NK, Gaur S. Percutaneous autogenous bone-marrow grafting in congenital tibial pseudarthrosis. J Bone Joint Surg Br. 1995;77:830-1.
11. Kitoh H, Kitakoji T, Tsuchiya H, Mitsuyama H, Nakamura H, Katoh M, et al. Transplantation of marrow-derived mesenchymal stem cells and platelet-rich plasma during distraction osteogenesis: a preliminary result of three cases. Bone. 2004;35:892-8. (Pubitemid 39349220)
12. Cho TJ, Choi IH, Lee KS, Lee SM, Chung CY, Yoo WJ, et al. Proximal tibial lengthening by distraction osteogenesis in congenital pseudarthrosis of the tibia. J Pediatr Orthop. 2007;27:915-20.
13. Tikkanen J, Leskelä HV, Lehtonen ST, Vähäsarja V, Melkko J, Ahvenjärvi L, et al. Attempt to treat congenital pseudar-throsis of the tibia with mesenchymal stromal cell transplantation. Cytotherapy. 2010;12:593-604.
14. Leskelä HV, Kuorilehto T, Risteli J, Koivunen J, Nissinen M, Peltonen S, et al. Congenital pseudarthrosis of neurofibroma-tosis type 1: impaired osteoblast differentiation and function and altered NF1 gene expression. Bone. 2009;44:243-50.
15. Granchi D, Devescovi V, Baglìo SR, Leonardi E, Donzelli O, Magnani M, et al. Biological basis for the use of autologous bone marrow stromal cells in the treatment of congenital pseudarthrosis of the tibia. Bone. 2010;46:780-8.
16. Kolanczyk M, Kossler N, Kühnisch J, Lavitas L, Stricker S, Wilkening U, et al. Multiple roles for neurofibromin in skeletal development and growth. Hum Mol Genet. 2007; 16:874-86. (Pubitemid 47062733)
17. Schindeler A, Little DG. Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1). Bone. 2008;42:616-22.
18. Kuorilehto T, Nissinen M, Koivunen J, Benson MD, Peltonen J. NF1 tumor suppressor protein and mRNA in skeletal tissues of developing and adult normal mouse and NF1-deficient embryos. J Bone Miner Res. 2004;19:983-9 (Pubitemid 41103455)
19. Neurofibromatosis. NIH Consens Statement Online 1987 Jul 13-15;6(12):1-19. http://consensus.nih.gov/1987/1987Neuro fibramatosis064html. htm 09/10/2009.
20. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classifi-cation of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte-and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009;27:158-67.
21. Savarino L, Cenni E, Tarabusi C, Dallari D, Stagni C, Cenac-chi A, et al. Evaluation of bone healing enhancement by lyophilized bone grafts supplemented with platelet gel: a standardized methodology in patients with tibial osteotomy for genu varus. J Biomed Mater Res B Appl Biomater. 2006;76:364-72. (Pubitemid 43165395)
22. Charnley J. Congenital pseudarthrosis of the tibia treated by intramedullary nail. J Bone Joint Surg Am. 1956;38:283-90.
23. Ciapetti G, Ambrosio L, Marletta G, Baldini N, Giunti A. Human bone marrow stromal cells: in vitro expansion and differentiation for bone engineering. Biomaterials. 2006;27: 6150-60. (Pubitemid 44414980)
24. Granchi D, Baglìo SR, Amato I, Giunti A, Baldini N. Para-crine inhibition of osteoblast differentiation induced by neu-roblastoma cells. Int J Cancer. 2008;123:1526-35.
25. Granchi D, Ochoa G, Leonardi E, Devescovi V, Baglìo SR, Osaba L, et al. Gene expression patterns related to osteogenic differentiation of bone marrow-derived mesenchymal stem cells during ex vivo expansion. Tissue Eng Part C Methods. 2010;16:511-24.
26. Mouritzen P, Noerholm M, Nielsen PS, Jacobsen N, Lomholt C, et al. ProbeLibrary: a new method for faster design and execution of quantitative real-time PCR. Nat Methods. 2005;4:313-6.
27. Hernigou P, Beaujean F. Bone marrow in patients with pseu-darthrosis. A study of progenitor cells by in vitro cloning. Rev Chir Orthop Reparatrice Appar Mot. 1997;83:33-40.
28. Seebach C, Henrich D, Tewksbury R, Wilhelm K, Marzi I. Number and proliferative capacity of human mesenchymal stem cells are modulated positively in multiple trauma patients and negatively in atrophic nonunions. Calcif Tissue Int. 2007;80:294-300. (Pubitemid 46675255)
29. Hofmann A, Ritz U, Hessmann MH, Schmid C, Tresch A, Rompe JD, et al. Cell viability, osteoblast differentiation, and gene expression are altered in human osteoblasts from hyper-trophic fracture non-unions. Bone. 2008;42:894-906.
30. Garrison KR, Shemilt I, Donell S, Ryder JJ, Mugford M, Harvey I, et al. Bone morphogenetic protein (BMP) for fracture healing in adults. The Cochran Library. 2010;6:1-52.
31. Anticevic D, Jelic M, Vukicevic S. Treatment of a congenital pseudarthrosis of the tibia by osteogenic protein-1 (bone mor-phogenetic protein-7): a case report. J Pediatr Orthop B. 2006;15:220-1.
32. Fabeck L, Ghafil D, Gerroudj M, Baillon R, Delincé P. Bone morphogenetic protein 7 in the treatment of congenital pseu-darthrosis of the tibia. J Bone Joint Surg Br. 2006;88:116-8. (Pubitemid 43125326)
33. Lee FY, Sinicropi SM, Lee FS, Vitale MG, Roye DP Jr, Choi IH. Treatment of congenital pseudarthrosis of the tibia with recombinant human bone morphogenetic protein-7 (rhBMP-7). A report of five cases. J Bone Joint Surg Am. 2006;88:627-33.
34. Kujala S, Vähäsarja V, Serlo W, Jalovaara P. Treatment of congenital pseudarthrosis of the tibia with native bovine BMP: a case report. Acta Orthop Belg. 2008;74:132-6.
35. Richards BS, Oetgen ME, Johnston CE. The use of rhBMP-2 for the treatment of congenital pseudarthrosis of the tibia: a case series. J Bone Joint Surg Am. 2010;92:177-85.
36. Kinsella CR Jr, Cray JJ, Durham EL, Burrows AM, Vecchione L, Smith DM, et al. Recombinant human bone morphoge-netic protein-2-induced craniosynostosis and growth restriction in the immature skeleton. Plast Reconstr Surg. 2011;127:1173-81.
37. Oetgen ME, Richards BS. Complications associated with the use of bone morphogenetic protein in pediatric patients. J Pediatr Orthop. 2010;30:192-8.
38. Gandhi A, Bibbo C, Pinzur M, Lin SS. The role of platelet-rich plasma in foot and ankle surgery. Foot Ankle Clin. 2005;10:621-37. (Pubitemid 41627812)
39. Cenni E, Savarino L, Perut F, Fotia C, Avnet S, Sabbioni G. Background and rationale of platelet gel in orthopaedic surgery. Musculoskelet Surg. 2010;94:1-8.
40. Arvidson K, Abdallah BM, Applegate LA, Baldini N, Cenni E, Gomez-Barrena E, et al. Bone regeneration and stem cells. J Cell Mol Med. 2011;15:718-46.
41. Griffin XL, Smith CM, Costa ML. The clinical use of platelet-rich plasma in the promotion of bone healing: a systematic review. Injury. 2009;40:158-62.
42. Tschon M, Fini M, Giardino R, Filardo G, Dallari D, Torri-celli P, et al. Lights and shadows concerning platelet products for musculoskeletal regeneration. Front Biosci (Elite Ed). 2011;3:96-107.
43. Visser LC, Arnoczky SP, Caballero O, Kern A, Ratcliffe A, Gardner KL. Growth factor-rich plasma increases tendon cell proliferation and matrix synthesis on a synthetic scaffold: an in vitro study. Tissue Eng Part A. 2010;16:1021-9.
44. Huang W, Yang S, Shao J, Li YP. Signaling and transcriptional regulation in osteoblast commitment and differentiation. Front Biosci. 2007;2:3068-92.
45. Ogata Y. Bone sialoprotein and its transcriptional regulatory mechanism. J Periodontal Res. 2008;43:127-35.
46. Motamed K. SPARC (osteonectin/BM-40). Int J Biochem Cell Biol. 1999;31:1363-6.
47. Kurtz A, Martuza RL. Antiangiogenesis in neurofibromatosis 1. J Child Neurol. 2002;17:578-84. (Pubitemid 35203618)
48. Kawachi Y, Xu X, Ichikawa E, Imakado S, Otsuka F. Expression of angiogenic factors in neurofibromas. Exp Dermatol. 2003;12:412-7. (Pubitemid 36992415)
49. Mashour GA, Ratner N, Khan GA, Wang HL, Martuza RL, Kurtz A. The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells. Oncogene. 2001;20: 97-105. (Pubitemid 32142342)